secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2026-05-14T12:31:16+00:00
Accession:  0001193125-26-222908
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 2.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen completes $5.3B Apellis acquisition; adds SYFOVRE/EMPAVELI, $41/share + CVRs
--------------------------------------------------------------------------------

- Biogen acquired Apellis for $41/share cash plus CVRs worth up to $4/share tied to SYFOVRE net sales milestones.
- Approximately 105.7M shares (82.4%) tendered; Merger completed under DGCL Section 251(h) without shareholder vote.
- Biogen borrowed $2B under a new credit agreement: $1B 364-day and $1B 2-year tranches to fund the acquisition.
- Apellis products EMPAVELI and SYFOVRE generated $689M net product revenue in 2025; deal expected to be accretive to Non-GAAP EPS in 2027.
- Biogen will provide updated financial guidance in Q2 2026 earnings report in July.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000119312526222908/0001193125-26-222908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000119312526222908/d109852d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-222908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer